Clinical trials: Genomic Testing
Small Cell Lung Cancer
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker…
- Trial name
- NCT05257551
- Testing
- Observation
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Tempus AI
Lung Neoplasms, Carcinoma Non-small-cell Lung
A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing
The investigators are doing this research to see if they can use small tissue samples or fluid to develop a test that will determine if the tissue samples are related or not related to each other.
- Trial name
- NCT02705404
- Testing
- Multifocal Tissue Banking
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Healthy Volunteers, Non-Healthy/Non-Frail
Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)
Background: Biomarkers are substances in people's blood and tissues. They help researchers understand diseases and signs of aging.
- Conditions
- Healthy Volunteers, Non-Healthy/Non-Frail, Frail
- Trial name
- NCT02339012
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Advanced Cancers
Genomic Profiling Assay in Phase I
The goal of this research study is to collect and test tumor tissue from patients with advanced cancers that may be enrolled in Phase 1 studies or other treatments.
- Trial name
- NCT02437617
- Testing
- Tumor Tissue
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Adenocarcinoma
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread…
- Trial name
- NCT05050084
- Testing
- Bicalutamide, Buserelin, Darolutamide
- Where
- 576 sites in United States, Canada
- Volunteers
- 2,050 people
- Sponsor
- NRG Oncology
Biliary Tract Cancer (BTC)
Bile ctDNA Genomic Profiling and Concordance With Tumor Tissue in Biliary Tract Cancer
This study is being done to find out whether bile fluid can be used to detect genetic changes in tumors of patients with advanced biliary tract cancer (BTC), such as cancer of the bile ducts or gallbladder.
- Trial name
- NCT07830628
- Testing
- Bile Sampling for ctDNA Analysis
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHA University
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Lung Cancer, Lymphoma
Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound
Aim: To investigate whether the novel 3rd generation FNB needle provides a better diagnostic accuracy than a standard FNA needle in EUS-B guided diagnosis of common deep seated thoracic malignancies (lung cancer and lymphoma).
- Conditions
- Lung Cancer, Lymphoma, Sarcoidosis
- Trial name
- IMPROVED (NCT06848738)
- Testing
- FNB, FNA
- Where
- 3 sites in Denmark
- Volunteers
- 362 people
- Sponsor
- Zealand University Hospital
Coronary Artery Disease, Angina Pectoris
Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease
The objective of this study is to collect data on the commercial use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood test to evaluate the clinical referral patterns of Primary Care Physicians after receipt of their…
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- REGISTRY-I (NCT01557855)
- Testing
- Corus CAD (ASGES)
- Where
- 7 sites in United States
- Volunteers
- 342 people
- Sponsor
- CardioDx
Endometrial Cancer
Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment
EUGENIE is a prospective multicentre interventional study, focused on improving endometrial cancer (EC) assessment by combining the new technique of genomic profiling with surgical extra uterine disease assessment.
- Trial name
- EUGENIE (NCT06354738)
- Testing
- total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Gasthuisberg
Thoracic Organ Transplantation
Genome Transplant Dynamics
Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early.
- Trial name
- NCT02423070
- Where
- 7 sites in United States
- Volunteers
- 991 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Prostate Cancer
Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance
Genomic Health's OncotypeDX® Prostate Cancer Assay is a commercially available laboratory test that measures the activity of certain genes in prostate cancer.
- Trial name
- NCT03502213
- Volunteers
- 489 people
- Sponsor
- Genomic Health®, Inc.
Colorectal Cancer
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
- Trial name
- STELLAR-316 (NCT07750158)
- Testing
- Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 13 sites in United States
- Volunteers
- 600 people
- Sponsor
- Exelixis
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
Cancer Predisposition Syndromes, Pediatric Cancer
Questionnaire on Congenital Cancer Signs Through Self-Assessment
This clinical trial tests whether a patient- and caregiver-completed questionnaire (QUOCCAS) can accurately help identify children and adolescents with cancer who may have an underlying cancer predisposition syndrome (CPS).
- Conditions
- Cancer Predisposition Syndromes, Pediatric Cancer, Childhood Neoplasms, Hereditary Cancer Syndromes
- Trial name
- QUOCCAS (NCT07378423)
- Testing
- Pre-Visit Preparation (PVP) Brochure, QUOCCAS Questionnaire, Germline genetic sequencing for Cancer Predisposition Syndromes (CPS)
- Where
- Switzerland
- Volunteers
- 205 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Soft Tissue Sarcoma, Advanced Cancer
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.
This trial is a multicenter, prospective cohort study aiming to describe molecular profiles of soft tissue sarcoma (STS) with complex genomic profiles in particular to assess the incidence of NTRK1/2/3, ROS1 or ALK gene fusions…
- Conditions
- Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer
- Trial name
- RNASARC (NCT03375437)
- Testing
- Blood and tumor samples
- Where
- 10 sites in France
- Volunteers
- 376 people
- Sponsor
- Centre Leon Berard
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Essential Hypertension
Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations
The principal aim of the study is to demonstrate that Rostafuroxin is able to induce a more pronounced reduction of arterial blood pressure respect to Losartan, in hypertensive patients carrying at least one of the pre-specified…
- Trial name
- NCT01320397
- Testing
- Rostafuroxin, Losartan
- Where
- 26 sites in Ireland, Italy and 1 more
- Volunteers
- 240 people
- Sponsor
- RostaQuo S.p.A.
Prostate Cancer, Prostate Cancer, Familial
Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a
This study was designed to compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches for risk assessment of prostate cancer and for chemoprevention of prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer, Familial, Hereditary Prostate Cancer
- Trial name
- NCT02381015
- Testing
- Genetic Risk Score: Number Format, Genetic Risk Score: Number + Pictograph, Family History: Number Format
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Pancreatic Cancer
Molecularly Tailored Therapy in Advanced Pancreatic Cancer
Pancreatic cancer that has spread or cannot be removed by surgery is difficult to treat. Standard chemotherapy can slow the disease, but the cancer often starts growing again.
- Trial name
- TAILOR-PANC (NCT07802418)
- Testing
- Arm 1: Molecularly Tailored Therapy, Arms 2: Standard-of-Care Therapy, Arm 3: Standard-of-Care Observational Cohort
- Where
- 4 sites in Denmark
- Volunteers
- 1,200 people
- Sponsor
- Herlev Hospital